ストックスクリーナーアプリを入手
8.72
0.68%
-0.06
アフターアワーズ：
8.60
-0.12
-1.38%
前日終値:
$8.78
開ける：
$8.72
24時間の取引高:
385.32K
Relative Volume:
0.93
時価総額：
$163.63M
収益：
$107.35M
当期純損益:
$6.84M
株価収益率:
24.69
EPS:
0.3532
ネットキャッシュフロー:
$14.64M
1週間 パフォーマンス:
+23.16%
1か月 パフォーマンス:
+33.54%
6か月 パフォーマンス:
-0.34%
1年 パフォーマンス:
-50.43%
1日の値動き範囲:
$8.4505
$9.08
1週間の範囲:
$6.568
$9.08
52週間の値動き範囲:
$4.54
$22.25
Optimizerx Corp Stock (OPRX) Company Profile
Compare OPRX vs VEEV, BTSG, TEM, HQY, TXG
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OPRX
Optimizerx Corp
|
8.72 | 132.11M | 107.35M | 6.84M | 14.64M | 0.3532 |
VEEV
Veeva Systems Inc
|
243.75 | 39.23B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
61.71 | 11.81B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
52.10 | 9.85B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
104.73 | 8.82B | 1.34B | 230.70M | 440.96M | 2.6695 |
TXG
10 X Genomics Inc
|
56.09 | 7.52B | 638.78M | -22.66M | 122.18M | -0.1744 |
Optimizerx Corp Stock (OPRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-08 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-12-20 | 開始されました | Stephens | Equal-Weight |
| 2024-07-25 | 再開されました | B. Riley Securities | Buy |
| 2024-04-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-01-03 | 開始されました | Barclays | Equal Weight |
| 2023-02-02 | 再開されました | B. Riley Securities | Buy |
| 2022-11-01 | 開始されました | Stifel | Buy |
| 2022-07-15 | 開始されました | SVB Leerink | Outperform |
| 2021-10-18 | 再開されました | B. Riley Securities | Buy |
| 2021-04-13 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-01-03 | 開始されました | William Blair | Outperform |
すべてを表示
Optimizerx Corp (OPRX) 最新ニュース
OptimizeRx Corp (OPRX) gains 6.7% institutional holder in Kennedy Capital - Stock Titan
Conferencia de resultados del segundo trimestre fiscal de 2026 de OptimizeRx (OPRX): Reitera previsiones mientras los ingresos caen un 30% - TradingKey
OptimizeRx (NASDAQ:OPRX) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
Citizens raises OptimizeRx stock price target on macro stability - Investing.com
Citizens raises OptimizeRx stock price target on macro stability By Investing.com - Investing.com Canada
Renaissance Technologies LLC Has $1.36 Million Stock Position in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx (OPRX) Fiscal Q2 2026 Earnings Call: Guidance Reaffirmed as Revenue Falls 30% - TradingKey
OptimizeRx Reaffirms 2026 Outlook Amid Revenue Decline - The Globe and Mail
OptimizeRx (OPRX) revenue falls 21% as margins and cash flow hold - Stock Titan
Stifel cuts OptimizeRx stock price target on revenue headwinds - Investing.com
OPTIMIZERx earnings beat by $0.06, revenue topped estimates - Investing.com Nigeria
OptimizeRx Corporation Q2 2026 Earnings Call Summary - Yahoo Finance
OptimizeRx Corp (OPRX) (Q2 2026) Earnings Call Highlights: Navigating Revenue Headwinds with ... - Yahoo! Finance Canada
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Technology Magazine
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth - Technology Magazine
OptimizeRx Q2 Earnings Call Highlights - MarketBeat
OPRX Looks 45.1% Undervalued on GF Value™ - GuruFocus
OptimizeRx Q2 adj. EPS beats estimate as sales fall 30% YoY - scanx.trade
Earnings call transcript: OptimizeRx beats Q2 2026 profit view as shares slip - Investing.com Australia
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
OptimizeRx (NASDAQ:OPRX) Announces Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
OptimizeRx Latest Results: FY2026 sales guidance affirmed at $95M-$100M - scanx.trade
OptimizeRx names Andy D’Silva as CFO, Heather Favazza as CAO By Investing.com - Investing.com UK
OptimizeRx (OPRX) Q2 2026 revenue falls 30% but company reaffirms full-year outlook - Stock Titan
OptimizeRx CFO Ed Stelmakh Will Advise Through End of 2027 - Stock Titan
OptimizeRx Refinances Debt With $35M Facility, Pays Down $8.3M - Stock Titan
OptimizeRx Set to Report Q2 2026 Results With Analyst Targets Pointing to Over 80% Upside - finance.biggo.com
Earnings To Watch: OptimizeRx Corp (OPRX) Q2 2026 -- GF Value Sees 106% Upside - Yahoo Finance
OptimizeRx Corp (OPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OPRX News | OPTIMIZERX CORP (NASDAQ:OPRX) - ChartMill
OptimizeRx Corp (OPRX) Stock News Today - TradingKey
OPRX|OptimizeRx Corp|Price:7.080|Chg%:+0.340 - TradingKey
Segall Bryant & Hamill LLC Invests $1.19 Million in OptimizeRx Corp. $OPRX - MarketBeat
OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
OptimizeRx Corp (OPRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET - The Manila Times
OptimizeRx Corp (OPRX) Cash Flow - TradingKey
OptimizeRx Corp (OPRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
OPRX|OptimizeRx Corp|Price:6.375|Chg%:+0.135 - TradingKey
OptimizeRx Corp (OPRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
OptimizeRx Corp (OPRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
OptimizeRx Corp (OPRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OptimizeRx Corp (OPRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TradingKey - TradingKey
OptimizeRx Corp (OPRX) Income Statement - TradingKey
OptimizeRx Corp (OPRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
OptimizeRx appoints Sarah Bast as chief marketing officer By Investing.com - Investing.com Nigeria
OptimizeRx appoints Sarah Bast as chief marketing officer - Investing.com
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer - The Manila Times
Press Release: OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer - Moomoo
Royce & Associates (OPRX) discloses 1.09M-share passive stake in OptimizeRx - Stock Titan
Optimizerx Corp (OPRX) 財務データ
収益
当期純利益
現金流量
EPS
1.10%
6.73%
大文字化:
|
ボリューム (24 時間):